Dapagliflozin 10 mg and Pioglitazone 15 mg Tablets: Uses, Dosage & Precautions
GLIDAPA PIO contains Dapagliflozin 10 mg and Pioglitazone 15 mg tablets and is marketed by Steris Healthcare. This combination brings together two antidiabetic medicines with different mechanisms of action and may be prescribed as part of an individualized treatment plan for adults with type 2 diabetes mellitus when appropriate.
Dapagliflozin helps lower blood glucose by increasing the urinary excretion of glucose, while pioglitazone improves the body's sensitivity to insulin. Together, these complementary actions can help improve glycemic control in appropriately selected patients.
What is GLIDAPA PIO Used For?
Dapagliflozin 10mg and Pioglitazone 15mg tablets are used for the management of type 2 diabetes mellitus along with a suitable diet, physical activity and other lifestyle measures.
Dapagliflozin belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, whereas pioglitazone belongs to the thiazolidinedione class.
The combination may be considered when additional glucose-lowering control is required and when both medicines are clinically appropriate for the patient.
It is not intended for treating type 1 diabetes or diabetic ketoacidosis.
Why is Dapagliflozin and Pioglitazone Important?
Type 2 diabetes is associated with elevated blood glucose caused by factors such as insulin resistance and impaired insulin secretion. Persistent high blood glucose can increase the risk of long-term complications affecting the heart, kidneys, eyes, nerves and blood vessels.
GLIDAPA PIO uses two complementary approaches. Dapagliflozin promotes glucose removal through the kidneys, while pioglitazone improves insulin sensitivity in tissues such as muscle and adipose tissue.
This dual mechanism can provide an additional option for achieving individualized blood-glucose targets when prescribed appropriately.
Key Benefits
What are the Benefits?
When prescribed appropriately, GLIDAPA PIO may provide the following benefits:
Helps lower elevated blood glucose in adults with type 2 diabetes.
Combines two complementary glucose-lowering mechanisms.
Dapagliflozin promotes urinary glucose excretion.
Pioglitazone improves insulin sensitivity.
May help improve overall glycemic control when diet and exercise alone are insufficient.
Can reduce the need for multiple separate tablets when a fixed-dose combination is clinically appropriate.
Dapagliflozin may also produce modest reductions in body weight and blood pressure in some patients. However, individual responses vary, and these effects should not be considered guaranteed benefits for every person.
Side Effects
Like all medicines, Dapagliflozin 10 mg and Pioglitazone 15 mg tablets can cause side effects.
Possible side effects include:
Increased urination
Thirst
Genital fungal infections
Urinary tract infections
Dizziness
Mild gastrointestinal discomfort
Headache
Weight gain
Fluid retention or swelling
Because dapagliflozin increases glucose excretion through urine, genital and urinary infections can occur in susceptible individuals.
Pioglitazone can cause fluid retention and weight gain, which are particularly important considerations in patients with heart-related conditions.
Serious Side Effects
Seek prompt medical attention if you experience:
Severe or rapidly increasing swelling
Unexplained shortness of breath
Rapid weight gain
Severe weakness or dehydration
Persistent vomiting or abdominal pain
Difficulty breathing
Symptoms of a serious allergic reaction
Pain, redness, swelling or tenderness around the genital or perineal region accompanied by fever or feeling unwell
Dapagliflozin can rarely be associated with diabetic ketoacidosis, which may occur even when blood glucose is not extremely high. Warning symptoms can include nausea, vomiting, abdominal pain, unusual tiredness and difficulty breathing.
Pioglitazone can worsen or precipitate heart failure in susceptible patients because of fluid retention.
Available Substitute
There is no single substitute that is suitable for everyone. Diabetes treatment should be individualized according to blood glucose levels, kidney function, cardiovascular status, weight, other medicines and treatment goals.
Depending on the patient's clinical needs, a healthcare professional may consider:
Dapagliflozin alone
Pioglitazone alone
Metformin-based combinations
SGLT2 inhibitor combinations
DPP-4 inhibitor combinations
GLP-1 receptor-based therapies
Insulin or other glucose-lowering medicines
Do not replace GLIDAPA PIO with another diabetes medicine without medical advice.
Dosage Guidelines
Take GLIDAPA PIO exactly as prescribed by your healthcare professional.
General guidance includes:
Take the tablet according to the prescribed schedule.
It may generally be taken with or without food unless your prescriber advises otherwise.
Swallow the tablet as directed.
Maintain adequate fluid intake unless you have been given fluid restrictions.
Do not take an extra dose to compensate for a missed dose unless specifically instructed.
Monitor blood glucose as recommended.
Continue appropriate dietary and physical-activity measures.
The suitability of the fixed-dose combination and the duration of treatment should be determined by the treating healthcare professional.
Precautions & Warnings
Before using Dapagliflozin 10 mg and Pioglitazone 15 mg tablets, inform your healthcare professional if you have:
Heart failure or a history of heart problems
Kidney disease
Liver disease
Recurrent urinary or genital infections
Low blood pressure or dehydration
A history of diabetic ketoacidosis
Bladder cancer or unexplained blood in the urine
Osteoporosis or a history of fractures
Planned surgery or prolonged fasting
Mechanism of Action
How Dapagliflozin Works
Dapagliflozin selectively inhibits SGLT2, a transporter responsible for much of the reabsorption of filtered glucose in the kidneys.
By inhibiting SGLT2, dapagliflozin reduces glucose reabsorption and increases the amount of glucose eliminated through urine. This lowers circulating blood glucose levels.
The increased urinary glucose excretion also produces an osmotic diuretic effect, which can contribute to increased urination and modest changes in body weight and blood pressure.
How Pioglitazone Works
Pioglitazone belongs to the thiazolidinedione class. It activates peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor involved in glucose and lipid metabolism.
Activation of PPAR-γ improves insulin sensitivity in peripheral tissues, including adipose tissue and skeletal muscle. This allows insulin to work more effectively and can improve glucose utilization.
Combined Action
The two medicines work through distinct pathways:
Dapagliflozin → increases urinary glucose excretion
Pioglitazone → improves insulin sensitivity
This complementary approach may help improve glycemic control in appropriately selected adults with type 2 diabetes.
How to Use
For safer treatment:
Take the medicine exactly as prescribed.
Monitor blood glucose according to your healthcare professional's instructions.
Maintain appropriate hydration.
Follow your recommended diet and physical-activity plan.
Report persistent genital or urinary symptoms.
Report swelling, rapid weight gain or breathlessness promptly.
Inform healthcare professionals before surgery or prolonged fasting.
Do not stop or change diabetes treatment without medical guidance.
Conclusion
GLIDAPA PIO, containing Dapagliflozin 10 mg and Pioglitazone 15 mg tablets, is marketed by Steris Healthcare and combines two antidiabetic medicines with different mechanisms of action for the management of type 2 diabetes mellitus.
Dapagliflozin lowers blood glucose by increasing urinary glucose excretion through SGLT2 inhibition, while pioglitazone improves insulin sensitivity through PPAR-γ activation. This complementary mechanism may provide effective glycemic management for appropriately selected patients.
Important safety considerations include dehydration, genital or urinary infections, diabetic ketoacidosis, fluid retention and potential worsening of heart failure. Kidney function and individual cardiovascular risk should be considered before and during treatment.
GLIDAPA PIO should be used only under appropriate medical supervision, together with a suitable diet, physical activity and regular diabetes monitoring.
Comments
Post a Comment